What dose of Femara (letrozole) do men use?
| Source | Strength and schedule | People |
|---|---|---|
| US label | One 2.5 mg tablet once a day1 | Postmenopausal women with breast cancer |
| US label, liver disease | 2.5 mg every other day1 | Patients with cirrhosis and severe hepatic dysfunction |
| UK SmPC | 2.5 mg once daily3 | Adult and elderly patients, with no adjustment for elderly patients; indicated for postmenopausal women with breast cancer |
Strength and label dose
The table is set at the top of the page
Femara is supplied as 2.5 mg tablets, in bottles of 30 on the US label.1 The US label says the tablets are taken orally without regard to meals.1 Its indication is postmenopausal women with breast cancer, and no use in men is listed.1
What trials in men used
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Sun et al. (2026) | Letrozole 2.5 mg once daily plus vitamin C 100 mg and vitamin E 100 mg, against the vitamins alone2 | 296 men with spermatogenic failure: 147 on letrozole, 149 on control | 3 months |
| Trunet et al. (1993) | Single doses from 0.02 to 30 mg across nine dose levels, and placebo, 3 men each4 | 18 healthy men | Single dose |
In 750 infertile women with polycystic ovary syndrome, Legro et al. gave letrozole 2.5 mg daily against clomiphene 50 mg daily, from cycle day 3 for 5 days, for up to five menstrual cycles, with a maximum letrozole dose of 7.5 mg (three pills) a day for 5 days.5 The sources do not define a letrozole "cycle" in men; the only cycle in a trial is the menstrual cycle.
TRT, cycles and what is not known
The Society for Endocrinology says evidence for aromatase inhibitors after non-medical androgen use is limited and of low quality.6 It says many men who stop or cycle in and out of such use self-administer so-called post-cycle therapy, typically hCG, SERMs or aromatase inhibitors.6 It says Rasmussen et al. randomised symptomatic men with a history of non-medical androgen use and low testosterone to letrozole or placebo, and that the study was terminated early because of poor recruitment; the statement gives no number of men.6 A ClinicalTrials.gov entry for the LUCAS trial (NCT05205837) planned 24 weeks of letrozole starting at 2.5 mg each day against placebo in men with hypogonadism after anabolic steroid use, with hCG 1500 IE twice weekly added after four weeks if testosterone had not reached its target; it was terminated for lack of recruitment, with an actual enrolment of 8.7 In Loves et al. (2013), a 6-month placebo-controlled trial in 42 obese men with a BMI over 35 kg/m2 and total testosterone under 10 nmol/l, letrozole started at one 2.5 mg tablet a week, with dose escalation every month until total testosterone reached 20 nmol/l.8 A ClinicalTrials.gov registry entry, NCT07922512, with no results posted, describes 60 men with oligospermia and a low testosterone to estradiol ratio, given letrozole 2.5 mg once daily for 3 months, against placebo.9 The sources report no human trial of letrozole with testosterone replacement or with clomiphene in men. No Femara or letrozole figure from Milligram's logs is shown.
Storage, mixing and syringes
The US label gives storage at 20°C to 25°C, with excursions permitted between 15°C and 30°C.1 The UK SmPC gives a 3-year shelf life, a 30°C ceiling, and storage in the original package against moisture.3
Neither label describes a liquid, powder or injectable Femara, or an instruction to dissolve, crush or split the tablet. With no concentration in mg per mL, no syringe mark applies.
Frequently asked questions
What does the Femara label say about safety?
The US label lists pregnancy as a contraindication because letrozole can cause fetal harm.1 In a label trial in women given letrozole or tamoxifen, median lumbar spine bone density fell 4.1% on letrozole and rose 0.3% on tamoxifen at 24 months.1 In the 2026 trial in 296 men with spermatogenic failure, decreased libido was reported in 12.2% of men on letrozole and 5.4% on vitamins alone.2
References
- Novartis (DailyMed). These highlights do not include all the information needed to use FEMARA safely and effectively. See full prescribing information for FEMARA. FEMARA (letrozole) tablets, for oral use Initial U.S. Approval: 1997. 2026. dailymed.nlm.nih.gov
- PMC. Letrozole and Infertility Among Males With Spermatogenic Failure. 2026. pmc.ncbi.nlm.nih.gov
- Novartis (emc). Femara 2.5 mg Tablets - Summary of Product Characteristics (SmPC) - (emc) | 1029. medicines.org.uk
- PubMed. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. 1993. pubmed.ncbi.nlm.nih.gov
- PMC. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. 2014. pmc.ncbi.nlm.nih.gov
- Society for Endocrinology. Management of non-medical androgen use: a position statement by the Society for Endocrinology. 2026. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT05205837: A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial. 2023. clinicaltrials.gov
- PubMed. Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia. 2013. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT07922512: Letrozole in Oligospermia With Eugonadotropic-Hypogonadism and Low Testosterone Estradiol Ratio. 2024. clinicaltrials.gov
- WADA. WORLD ANTI-DOPING CODE. wada-ama.org